Abcam, ab283718, Anti-TCF-4/TCF7L2+TCF-3/TCF7L1 antibody [EPR24701-87] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal TCF-4/TCF7L2 antibody. Carrier free. Suitable for WB and reacts with Mouse, Rat, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24701-87,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab283718 is the carrier-free version of
ab272235
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TCF3 also known as E2A TCF-4/TCF7L2 and TCF-3/TCF7L1 are transcription factors that control gene expression by binding DNA at unique sites. This complex includes proteins that serve as key modulators in gene transcription influenced by the Wnt signaling pathway. TCF3 is approximately 65 kDa while TCF7L2 is about 75 kDa. These proteins express in many tissues including the brain liver and intestine reflecting their fundamental role in numerous cellular functions.
Biological function summary
TCF3 and its related proteins are involved in regulating cell differentiation and proliferation. They interact as part of the Wnt signaling pathway which is critical for embryonic development and tissue homeostasis. These proteins also play roles in maintaining stem cell populations. By forming complexes with other proteins like beta-catenin TCF proteins can activate or repress target gene expression allowing responsive regulation of cellular activity.
Pathways
The TCF proteins function mainly in the Wnt signaling and Notch pathways central to cell fate decisions. In the Wnt signaling pathway TCF proteins especially TCF7L2 interact with beta-catenin to regulate the transcription of Wnt target genes. In the Notch pathway these proteins contribute indirectly by influencing cellular interactions that affect Notch signaling outcomes. Both pathways highlight TCF's importance in developmental and cellular processes.
The TCF proteins have strong associations with cancer and type 2 diabetes. Mutations in the TCF7L2 gene link to an increased risk of type 2 diabetes influencing insulin secretion and glucose metabolism. Furthermore aberrant Wnt/TCF signaling contributes to tumorigenesis and cancer progression with proteins like TCF7L2 acting as potential therapeutic targets. The understanding of these proteins could lead to advances in treatment strategies for these conditions.